GLYC Logo

GlycoMimetics, Inc. (GLYC) 

NASDAQ$0.2596
Market Cap
$16.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
308 of 925
Rank in Industry
176 of 528

GLYC Insider Trading Activity

GLYC Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$83,159325
Sells
$488,749975

Related Transactions

Rock EdwinChief Medical Officer2$78,8250$0$78,825
Hahn Brian M.SVP Finance, CFO1$4,3350$0$4,335
Invus Public Equities, L.P.10 percent owner0$09$488,749$-488,749

About GlycoMimetics, Inc.

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect â€¦

Insider Activity of GlycoMimetics, Inc.

Over the last 12 months, insiders at GlycoMimetics, Inc. have bought $83,159 and sold $488,749 worth of GlycoMimetics, Inc. stock.

On average, over the past 5 years, insiders at GlycoMimetics, Inc. have bought $2.17M and sold $2.74M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Rock Edwin (Chief Medical Officer) — $78,825. Hahn Brian M. (SVP Finance, CFO) — $4,335.

The last purchase of 115,000 shares for transaction amount of $30,717 was made by Rock Edwin (Chief Medical Officer) on 2024‑06‑21.

List of Insider Buy and Sell Transactions, GlycoMimetics, Inc.

2024-08-08SaleInvus Public Equities, L.P.10 percent owner
260,873
0.4135%
$0.19$50,009+34.59%
2024-08-07SaleInvus Public Equities, L.P.10 percent owner
61,488
0.0996%
$0.18$11,197+44.72%
2024-08-06SaleInvus Public Equities, L.P.10 percent owner
55,732
0.0882%
$0.18$10,188+40.79%
2024-08-05SaleInvus Public Equities, L.P.10 percent owner
164,523
0.2612%
$0.19$30,996+36.99%
2024-08-02SaleInvus Public Equities, L.P.10 percent owner
286,200
0.4383%
$0.20$57,354+24.24%
2024-08-01SaleInvus Public Equities, L.P.10 percent owner
63,564
0.0987%
$0.22$13,743+16.76%
2024-07-30SaleInvus Public Equities, L.P.10 percent owner
756,835
1.1897%
$0.22$167,185+15.18%
2024-07-29SaleInvus Public Equities, L.P.10 percent owner
363,949
0.5697%
$0.24$85,637+7.63%
2024-07-26SaleInvus Public Equities, L.P.10 percent owner
258,335
0.4016%
$0.24$62,440+4.02%
2024-06-21PurchaseRock EdwinChief Medical Officer
115,000
0.1787%
$0.27$30,717+0.47%
2024-06-20PurchaseRock EdwinChief Medical Officer
190,000
0.2799%
$0.25$48,108+3.16%
2024-06-18PurchaseHahn Brian M.SVP Finance, CFO
17,500
0.0252%
$0.25$4,335+6.32%
2023-09-22PurchaseRock EdwinChief Medical Officer
30,403
0.0463%
$1.38$41,956-0.71%
2023-09-21PurchaseRock EdwinChief Medical Officer
35,000
0.0544%
$1.38$48,300+2.17%
2023-05-17SaleHahn Brian M.SVP Finance, CFO
3,700
0.0059%
$1.95$7,215-15.69%
2023-05-10PurchaseJUNIUS DANIEL Mdirector
30,000
0.0441%
$1.56$46,800-1.14%
2023-05-08PurchaseJohnson Bruce SSVP & Chief Commercial Officer
13,500
0.0237%
$1.57$21,195+18.24%
2023-02-24PurchaseInvus Public Equities, L.P.10 percent owner
100,000
0.1667%
$1.70$170,000-5.03%
2023-02-23PurchaseInvus Public Equities, L.P.10 percent owner
200,000
0.3399%
$1.75$350,760-5.85%
2023-02-22PurchaseInvus Public Equities, L.P.10 percent owner
150,000
0.2504%
$1.79$268,995-9.55%
Total: 84
*Gray background shows transactions not older than one year

Insider Historical Profitability

2.47%
Invus Public Equities, L.P.10 percent owner
6317565
9.7926%
$1.64M89<0.0001%
Rock EdwinChief Medical Officer
680403
1.0547%
$176,632.6270<0.0001%
Hahn Brian M.SVP Finance, CFO
70643
0.1095%
$18,338.9223+31.85%
BVF PARTNERS L P/IL10 percent owner
4980812
7.7205%
$1.29M30<0.0001%
BARRIS PETER J10 percent owner
4702791
7.2896%
$1.22M12<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$992,222,850
90
-12.52%
$19.11M
$8,900,811
57
-24.79%
$14.9M
$6,204,522
45
1.91%
$18.93M
GlycoMimetics, Inc.
(GLYC)
$85,897,100
36
2.47%
$16.75M
$217,684
34
1.61%
$17.84M

GLYC Institutional Investors: Active Positions

Increased Positions22+47.83%16M+91.35%
Decreased Positions16-34.78%4M-20.74%
New Positions16New16MNew
Sold Out Positions11Sold Out3MSold Out
Total Postitions52+13.04%30M+70.62%

GLYC Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Bvf Inc/Il$2,596.0014.68%9.54M00%2024-12-31
Logos Global Management Lp$1,469.008.31%5.4M+5MNew2024-12-31
Adage Capital Partners Gp, L.L.C.$1,385.007.83%5.09M+5MNew2024-12-31
Vr Adviser, Llc$816.004.62%3M+3MNew2024-12-31
Vanguard Group Inc$726.004.11%2.67M00%2024-12-31
Wellington Management Group Llp$384.002.17%1.41M+1MNew2024-12-31
Blackrock, Inc.$198.001.12%728,637+779+0.11%2024-12-31
Geode Capital Management, Llc$142.000.8%521,22300%2024-12-31
Jefferies Financial Group Inc.$115.000.65%423,777+423,777New2024-12-31
Adar1 Capital Management, Llc$90.000.51%331,827+286,127+626.1%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
2SellsBuysStrong BuyBuyHoldSellStrong Sell